GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Additional Paid-In Capital

NurExone Biologic (FRA:J90) Additional Paid-In Capital : €18.59 Mil(As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is NurExone Biologic Additional Paid-In Capital?


NurExone Biologic's quarterly additional paid-in capital increased from Jun. 2024 (€15.63 Mil) to Sep. 2024 (€16.02 Mil) and increased from Sep. 2024 (€16.02 Mil) to Dec. 2024 (€18.59 Mil).

NurExone Biologic's annual additional paid-in capital increased from Dec. 2022 (€10.62 Mil) to Dec. 2023 (€12.20 Mil) and increased from Dec. 2023 (€12.20 Mil) to Dec. 2024 (€18.59 Mil).

NurExone Biologic Additional Paid-In Capital Historical Data

The historical data trend for NurExone Biologic's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NurExone Biologic Additional Paid-In Capital Chart

NurExone Biologic Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
2.88 10.62 12.20 18.59

NurExone Biologic Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.20 15.18 15.63 16.02 18.59

NurExone Biologic Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

NurExone Biologic Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NurExone Biologic's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

NurExone Biologic Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NurExone Biologic Inc (FRA:J90) » Definitions » Additional Paid-In Capital
Comparable Companies
TSXV:SHRX TSX:HBP TSX:ONC TSX:MBX XCNQ:DTC TSXV:MIR NEOE:ONCO TSX:SVA TSXV:TTI TSXV:COV VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NRXBF:USA NRX:Canada
Address
1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
Website
https://www.nurexone.com
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Their primary product is ExoTherapy, which is an exosome therapy production platform. The company has two business lines. Firstly, it is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). Secondly, it aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.

NurExone Biologic Headlines

No Headlines